›Publications›Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study., Target Oncol, 2023, 18, 585-591. [IF = 5.4]. Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study., Target Oncol, 2023, 18, 585-591. [IF = 5.4]. Auteurs : Babey, H ; Jamme, P ; Curcio, H ; Assié, JB ; Veillon, R ; Doubre, H & al (Guisier F) Revue : Target Oncol Année : 2023 Groupe : QuantIF ← Retour aux publications